KRAS and non-small cell lung carcinoma: The total ORR to chemotherapy was 35.8% (138/385) in KRAS mutant patients and 45.1% (381/845) in KRAS and EGFR wild-type patients based on eight studies [8, 10, 15, 27, 28, 32, 50, 51] conducted in stage IIIb-IV unresectable NSCLC.